The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global nucleic acid testing market size reached US$ 2.65 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 3.93 Billion by 2027, exhibiting a growth rate (CAGR) of 6.67% during 2022-2027.
Nucleic acid testing (NAT) refers to a molecular technique for screening viruses, bacteria or pathogenic nucleic acid in the blood, tissue or urine of the patient. It is conducted for forensic testing and to diagnose transfusion-transmitted infections, genetic diseases and cancer. It involves sample pooling through nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection. The testing involves kits and consumables for performing polymerase chain reaction (PCR), strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) and NA sequence-based amplification (NASBA) processes. NAT is also used for the identification of diseases with no visible symptoms and resolving false reactive interpretations.
The increasing prevalence of infectious bacterial and viral diseases across the globe represents one of the key factors driving the growth of the market. Furthermore, the increasing demand for advanced diagnostic systems is also driving the market growth. In line with this, the onset of the coronavirus disease (COVID-19) has also enhanced the demand for NAT solutions to detect the antigens. NAT is widely used for the effective management of communicable diseases and accurate identification of the infecting agent. Additionally, various technological advancements, such as the development of novel biological diagnostic techniques, including signal and probe amplification systems, are acting as other growth-inducing factors. These innovative techniques aid in the early detection of the disease and minimizing the infectious period of the virus. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global nucleic acid testing market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, technology and end user.
Breakup by Product Type:
Breakup by Technology:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, Siemens Healthcare, Tecan Group AG and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Technology, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, Siemens Healthcare, Tecan Group AG and Thermo Fisher Scientific Inc|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at